See more : Nova Ltd. (NVMI) Income Statement Analysis – Financial Results
Complete financial analysis of Vijaya Diagnostic Centre Limited (VIJAYA.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vijaya Diagnostic Centre Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- V.F. Corporation (0R30.L) Income Statement Analysis – Financial Results
- The RealReal, Inc. (REAL) Income Statement Analysis – Financial Results
- Henan Shenhuo Coal & Power Co.,Ltd (000933.SZ) Income Statement Analysis – Financial Results
- Danske Invest Global Indeks Udb (DKIGI.CO) Income Statement Analysis – Financial Results
- Quicklizard Ltd (QLRD.TA) Income Statement Analysis – Financial Results
Vijaya Diagnostic Centre Limited (VIJAYA.BO)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.vijayadiagnostic.com
About Vijaya Diagnostic Centre Limited
Vijaya Diagnostic Centre Limited engages in the provision of diagnostic services for patients in India. It offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, CT scan, magnetic resonance imaging (MRI) scan, ultrasound, digital X-ray, cardiology, gastroenterology, nuclear medicine and PET/CT, multidetector computed tomography scan, and MRI-3T services. The company also provides health checkups and home sample collection services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyderabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 5.48B | 4.59B | 4.62B | 3.76B | 3.39B | 2.92B |
| Cost of Revenue | 863.73M | 588.82M | 714.99M | 570.95M | 439.06M | 404.78M |
| Gross Profit | 4.61B | 4.00B | 3.91B | 3.19B | 2.95B | 2.52B |
| Gross Profit Ratio | 84.23% | 87.18% | 84.54% | 84.83% | 87.04% | 86.16% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 911.80M | 935.80M | 622.88M | 485.89M | 526.79M | 472.49M |
| Selling & Marketing | 77.01M | 57.35M | 46.08M | 31.45M | 53.26M | 52.70M |
| SG&A | 988.81M | 993.15M | 668.96M | 517.34M | 580.05M | 525.19M |
| Other Expenses | 0.00 | 141.51M | 128.31M | 16.09M | 9.18M | 18.53M |
| Operating Expenses | 985.79M | 2.80B | 2.40B | 2.03B | 2.11B | 1.83B |
| Cost & Expenses | 1.85B | 3.39B | 3.11B | 2.60B | 2.55B | 2.24B |
| Interest Income | 59.73M | 82.80M | 97.99M | 95.96M | 42.63M | 28.65M |
| Interest Expense | 239.90M | 209.48M | 164.50M | 135.09M | 139.27M | 122.50M |
| Depreciation & Amortization | 569.96M | 617.20M | 526.86M | 504.51M | 491.70M | 396.26M |
| EBITDA | 2.21B | 1.96B | 2.16B | 1.77B | 1.48B | 1.18B |
| EBITDA Ratio | 40.32% | 42.72% | 46.83% | 46.76% | 40.30% | 38.16% |
| Operating Income | 3.63B | 1.23B | 1.53B | 1.18B | 849.13M | 694.04M |
| Operating Income Ratio | 66.24% | 26.71% | 33.05% | 31.21% | 25.07% | 23.73% |
| Total Other Income/Expenses | -2.04B | -91.51M | -54.14M | -53.84M | -1.67M | -32.15M |
| Income Before Tax | 1.59B | 1.14B | 1.47B | 1.12B | 834.27M | 653.18M |
| Income Before Tax Ratio | 28.97% | 24.72% | 31.88% | 29.78% | 24.63% | 22.33% |
| Income Tax Expense | 390.44M | 283.03M | 367.17M | 269.97M | 209.20M | 190.46M |
| Net Income | 1.19B | 846.32M | 1.10B | 844.78M | 625.38M | 458.74M |
| Net Income Ratio | 21.69% | 18.43% | 23.72% | 22.44% | 18.47% | 15.69% |
| EPS | 11.62 | 8.29 | 10.76 | 8.28 | 6.13 | 4.50 |
| EPS Diluted | 11.59 | 8.26 | 10.69 | 8.28 | 6.13 | 4.50 |
| Weighted Avg Shares Out | 102.22M | 102.04M | 101.97M | 101.97M | 101.97M | 101.90M |
| Weighted Avg Shares Out (Dil) | 102.52M | 102.48M | 102.57M | 101.99M | 102.01M | 101.90M |
Source: https://incomestatements.info
Category: Stock Reports